The purpose of this study was to evaluate performance feedback delivered by on-site presentations compared to mailed feedback on improving acute myocardial infarction (AMI) care. We used a randomized trial including 18 hospitals nested within the Cooperative Cardiovascular Project. Patients comprised AMI Medicare patients admitted before (n = 929, 1994 and 1995) and after intervention (n = 438, 1996). Control hospitals received written feedback by mail. The experimental intervention group received a presentation led by a cardiologist and a quality improvement specialist. We assessed the proportion of patients receiving appropriate AMI care before and after the intervention. Both univariate and multivariate analyses demonstrated no effect of the intervention in increasing the proportion of patients who received reperfusion, aspirin, beta-blockers, or angiotensin-converting enzyme in- hibitors. On-site feedback presentations were not associated with a larger improvement in AMI care compared to the mailed feedback. Other interventions, such as opinion leaders and patient-directed interventions, may be necessary in order to improve the care of AMI patients.
US Bureau of the Census. Statistical Abstract of the United States: 1997. 117th ed.Washington, DC; 1997.
2.
Hennekens CH, Buring JE, Sandercock P, et al.Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749-756.
3.
Lau J, Antman EM, Jimenez-Silva J, et al.Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248-254.
4.
Fuster V, Dyken ML, Vokonas PS, et al.Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-675.
5.
Collins R, Peto R, Baigentt C, et al.Aspirin, heparin, and fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 1997;336:847-860.
6.
Ryan TJ, Anderson JL, Antman EM, et al.ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Management of Acute Myocardial Infarction). JAm Coll Cardiol. 1996;28:1328-1419.
7.
Lamas GA, Pfeffer MA, Hamm P, et al.Do the results of randomized clinical trials of cardiovascular drugs influence medical practice?N Engl J Med. 1992;327:241-247.
8.
Hennekens CH, Jonas MA, Buring JE. The benefits of aspirin in acute myocardial infarction: still a well-kept secret in United States. Arch Intern Med. 1994;154:37-39.
9.
Col NF, McLaughlin TJ, Soumerai SB, et al.The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study. Arch Intern Med. 1996;156:54-60.
10.
McLaughlin TJ, Soumerai SB, Willison DJ, et al.Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med. 1996;156:799-805.
11.
Ellerbeck EF, Jencks SF, Radford MJ, et al.Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the cooperative cardiovascular project. JAMA. 1995;273:1509-1514.
12.
Krumholz HM, Murillo JE, Chen J, et al.Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA. 1997;277:1683-1688.
13.
Marciniak TA, Ellerbeck EF, Radford MJ, et al.Improving the quality of care for Medicare patients with acute myocardial infarction: results from the cooperative cardiovascular project. JAMA. 1998;279:1351-1357.
14.
Krumholz HM, Friesinger GC, Cook F, et al.Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction. JAm Geriatr Soc. 1994;42:127-131.
15.
Gurwitz JH, Goldberg RJ, Gore JM. Coronary thrombolysis for the elderly?JAMA. 1991;265:1720-1723.
16.
Gurwitz JH, Goldberg RJ. Coronary thrombolysis for the elderly: is clinical practice really lagging behind evidence of benefit?JAMA. 1997;277:1723-1724.
17.
Soumerai SB, McLaughlin TJ, Gurwitz JH, et al.Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA. 1998;279:1358-1363.
Dicker RC, Ordin DL, Han LF, et al.Introducing the Medicare Quality of Care Surveillance System. Quality Resume No. 1. Baltimore, Md: Health Care Financing Administration; 1997.
20.
Lomas J, Enkin M, Anderson GM, et al.Opinion leaders vs audit and feedback to implement practice guidelines: delivery after previous cesarean section. JAMA. 1991;265:2202-2207.
21.
Stross JK, Bole GG. Evaluation of a continuing education program in rheumatoid arthritis. Arthritis Rheum. 1980;23:846-849.
22.
Jencks SF, Daley J, Draper D, et al.Interpreting hospital mortality data. The role of clinical risk adjustment. JAMA. 1988; 260:3611-3616.
23.
Knaus WA, Draper EA, Wagner DP, et al.APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
24.
Ludwigs U, Hulting J. Acute Physiology and Chronic Health Evaluation II scoring system in acute myocardial infarction: a prospective validation study. Crit Care Med. 1995;23:854-859.
25.
Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons Inc; 1989.
26.
Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
27.
Lambert-Huber DA, Ellerbeck EF, Wallace RG, et al.Quality of care indicators for patients with acute myocardial infarction: pilot validation of the indicators. Clin Performance Qual Health Care. 1994;2:219-222.
28.
Davis DA, Thompson MA, Oxman AD, et al.Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA. 1995;274:700-705.
29.
Soumerai SB, Avorn J. Principles of educational outreach ("Academic Detailing") to improve clinical decision making. JAMA. 1990;263:549-556.
30.
Stross JK, Hiss RG, Watts CM, et al.Continuing education in pulmonary disease for primary-care physicians. Am Rev Respir Dis. 1983;27:739-746.
31.
Soumerai SB, Avorn J. Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Health Soc. 1984;62:447-474.
32.
Anderson FA, Wheeler HB, Goldberg RJ, et al.Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med. 1994;154:669-677.
33.
Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet. 1994;343:311-322.
34.
Tversky A, Kahneman D. Judgement under uncertainty: heuristics and biases. Science. 1974;185:1124-1131.
35.
Beyth RJ, Antani MR, Covinsky KE, et al.Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation?J Gen Intern Med. 1996;11:721-728.
36.
Gurwitz JH, McLaughlin TJ, Willison DJ, et al.Delayed hospital presentation in patients who have had acute myocardial infarction. Ann Intern Med. 1997;126:593-598.
